Arini-Lazard Fund Wins $200 Million From BCI Pension Fund
British Columbia Investment Management Corp. has made a $200 million anchor investment in a Europe-focused private credit fund launched by Arini Capital Management as part of the firm's alliance with Lazard Inc.
The Victoria-based pension fund manager, which oversees C$250.4 billion ($183 billion) in assets, also plans to allocate more than $400 million in additional co-investments alongside the fund, according to a statement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 15,000,000 shares of common stock. The shares of common stock and accompanying common warrants were offered collectively at a price to the public of $3.00 per share and accompanying common warrant. Achieve has also granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock and/or accompanying common warrants to purchase up to an additional 2,250,000 shares of common stock (or pre-funded warrants in lieu thereof) in connection with the public offering. Each common warrant will be exercisable, at the purchaser's election, for either common stock at an exercise price of $3.00 per share or for pre-funded warrants, with an exercise price of $2.999 per pre-funded warrant. Such common stock warrants are exercisable any time after the date of issuance, subject to certain ownership limitations, and will expire five years from the date of issuance. All of the securities are being offered by Achieve. The offering is expected to close on or about June 30, 2025, subject to the satisfaction of customary closing conditions. Citizens Capital Markets and Raymond James are acting as the joint book-running managers in the offering. Lake Street Capital Markets, LLC is acting as financial advisor to Achieve in the offering. The aggregate gross proceeds from this offering are expected to be approximately $45.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Achieve. Achieve intends to use the proceeds from the offering to fund continued advancement of cytisinicline through potential U.S. Food and Drug Administration marketing approval of cytisinicline and for working capital and general corporate purposes. The securities are being offered by Achieve pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC). A final prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at Copies of the final prospectus supplement and accompanying base prospectus may also be obtained, when available, from: Citizens Capital Markets, at 450 Park Avenue, 5th Floor, New York, NY 10022, or by calling (415) 835-8985, or by email at syndicate@ and Raymond James at Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, or by email at prospectus@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Achieve, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Achieve Life Sciences, Inc. Achieve Life Sciences is a late-stage specialty pharmaceutical company committed to addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. In June 2025, the company submitted its New Drug Application to the FDA for cytisinicline as a treatment of nicotine dependence for smoking cessation in adults, based on two successfully completed Phase 3 studies and its fully enrolled open-label safety study. Additionally, the company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. About CytisiniclineThere are approximately 29 million adults in the United States who smoke combustible cigarettes.1 Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.2,3 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.3 In addition, there are approximately 17 million adults in the United States who use e-cigarettes, also known as vaping.4 In 2024, approximately 1.6 million middle and high school students in the United States reported using e-cigarettes.5 There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. Cytisinicline has been granted Breakthrough Therapy designation by the FDA to address this critical need. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products. Cytisinicline is an investigational product candidate being developed as a treatment of nicotine dependence for smoking cessation and has not been approved by the Food and Drug Administration for any indication in the United States. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing, size and expected gross proceeds of the offering, the expected use of the proceeds, the satisfaction of customary closing conditions related to the offering and sale of securities, Achieve's ability to complete the offering, the timing and nature of cytisinicline clinical development and regulatory review and approval, data results and commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, and the successful commercialization of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. There can be no assurance regarding the completion of this offering. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, , including those risks described in the risk factors set forth in Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law. Investor Relations ContactNicole Jonesir@ 686-1510 References1VanFrank B, Malarcher A, Cornelius ME, Schecter A, Jamal A, Tynan M. Adult Smoking Cessation — United States, 2022. MMWR Morb Mortal Wkly Rep 2024;73:633–641.2World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.3U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.4Vahratian A, Briones EM, Jamal A, Marynak KL. Electronic cigarette use among adults in the United States, 2019–2023. NCHS Data Brief, no 524. Hyattsville, MD: National Center for Health Statistics. 2025. DOI: 10.15620/cdc/174583.5Jamal A, Park-Lee E, Birdsey J, et al. Tobacco Product Use Among Middle and High School Students — National Youth Tobacco Survey, United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:917–924.
Yahoo
an hour ago
- Yahoo
3 Middle Eastern Dividend Stocks Yielding Up To 7.9%
As Gulf shares rise amid a holding ceasefire between Israel and Iran, Dubai's stock index has reached a 17-year high, reflecting the region's buoyant market sentiment. In this environment of stability and growth, dividend stocks become particularly attractive for investors seeking steady income streams while capitalizing on favorable market conditions. Name Dividend Yield Dividend Rating Saudi Telecom (SASE:7010) 9.69% ★★★★★☆ Saudi National Bank (SASE:1180) 5.56% ★★★★★☆ Saudi Awwal Bank (SASE:1060) 6.01% ★★★★★☆ Riyad Bank (SASE:1010) 6.42% ★★★★★☆ National Bank of Ras Al-Khaimah (P.S.C.) (ADX:RAKBANK) 7.35% ★★★★★☆ Emirates NBD Bank PJSC (DFM:EMIRATESNBD) 4.35% ★★★★★☆ Emaar Properties PJSC (DFM:EMAAR) 7.43% ★★★★★☆ Commercial Bank of Dubai PSC (DFM:CBD) 5.81% ★★★★★☆ Arab National Bank (SASE:1080) 6.03% ★★★★★☆ Anadolu Hayat Emeklilik Anonim Sirketi (IBSE:ANHYT) 7.62% ★★★★★☆ Click here to see the full list of 76 stocks from our Top Middle Eastern Dividend Stocks screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Dividend Rating: ★★★★★☆ Overview: Anadolu Hayat Emeklilik Anonim Sirketi offers individual and group insurance and reinsurance services in life, retirement, and personal accident sectors in Turkey, with a market cap of TRY32.79 billion. Operations: Anadolu Hayat Emeklilik Anonim Sirketi generates revenue through its individual and group insurance and reinsurance services in the life, retirement, and personal accident sectors within Turkey. Dividend Yield: 7.6% Anadolu Hayat Emeklilik Anonim Sirketi offers a compelling dividend yield of 7.62%, ranking in the top 25% of Turkey's market. Despite an unstable and volatile dividend history over the past decade, recent dividend growth is notable. The company's dividends are sustainably covered by earnings (56.6% payout ratio) and cash flows (36.5% cash payout ratio). With a low price-to-earnings ratio of 7.4x compared to the market, it presents good value for investors seeking income opportunities in the Middle East region. Dive into the specifics of Anadolu Hayat Emeklilik Anonim Sirketi here with our thorough dividend report. Upon reviewing our latest valuation report, Anadolu Hayat Emeklilik Anonim Sirketi's share price might be too pessimistic. Simply Wall St Dividend Rating: ★★★★★☆ Overview: Saudi Awwal Bank, operating in the Kingdom of Saudi Arabia, offers a range of banking and financial services through its subsidiaries and has a market cap of SAR67.40 billion. Operations: Saudi Awwal Bank generates its revenue from several key segments, including Treasury (SAR1.91 billion), Capital Markets (SAR439.67 million), Wealth & Personal Banking (SAR4.06 billion), and Corporate and Institutional Banking (SAR7.15 billion). Dividend Yield: 6% Saudi Awwal Bank offers a dividend yield of 6.02%, placing it in the top 25% of dividend payers in Saudi Arabia. Despite a history of volatility, dividends are currently covered by earnings with a payout ratio of 52.7%. The recent issuance of USD 650 million Green Sukuk could support future financial stability. Its price-to-earnings ratio is attractively low at 8.8x, suggesting good value relative to the market and peers. Unlock comprehensive insights into our analysis of Saudi Awwal Bank stock in this dividend report. According our valuation report, there's an indication that Saudi Awwal Bank's share price might be on the cheaper side. Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Computer Direct Group Ltd. operates in the computing and software industry in Israel, with a market cap of ₪1.64 billion. Operations: Computer Direct Group Ltd.'s revenue is primarily derived from three segments: Infrastructure and Computing (₪1.28 billion), Outsourcing of Business Processes and Technology Support Centers (₪326.89 million), and Technological Solutions and Services, Management Consulting, and Value-Added Services (₪2.57 billion). Dividend Yield: 8% Computer Direct Group's dividend yield of 7.96% ranks in the top 25% of Israeli dividend payers, yet its sustainability is questionable due to a high payout ratio of 148.3%, indicating dividends aren't covered by earnings. However, cash flows cover dividends well with a cash payout ratio of 31.5%. Although dividends have grown over the past decade, they remain volatile and unreliable. Recent earnings growth shows improvement, with Q1 sales at ILS 1.13 billion and net income rising to ILS 22.17 million year-over-year. Take a closer look at Computer Direct Group's potential here in our dividend report. Our expertly prepared valuation report Computer Direct Group implies its share price may be lower than expected. Get an in-depth perspective on all 76 Top Middle Eastern Dividend Stocks by using our screener here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include IBSE:ANHYT SASE:1060 and TASE:CMDR. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Booking Holdings Best Positioned in Travel Sector, Says Piper Sandler After Executive Meetings
Booking Holdings Inc. (NASDAQ:BKNG) ranks among the best consumer discretionary stocks to buy now. With a price target of $5,077, Piper Sandler reaffirmed its Neutral rating on Booking Holdings Inc. (NASDAQ:BKNG) on June 18 following recent management meetings with company executives. As a means to explore different facets of the company's operations and strategy, the investment firm's analyst team met with Grace Lee, SVP of Investor Relations and FP&A at Booking Holdings Inc. (NASDAQ:BKNG), and Mike Reilly, Senior Director of IR and FP&A. The expansion of alternative accommodations, the macroeconomic climate, artificial intelligence projects, marketing effectiveness, and the competitive landscape in the internet travel industry were among the main subjects discussed during these talks. Although Piper Sandler remained neutral regarding the larger online travel sector, it did concede that Booking Holdings Inc. (NASDAQ:BKNG) 'remains best positioned given end market exposure and solid execution' in comparison to its competitors. Booking Holdings Inc. (NASDAQ:BKNG) offers traditional and online reservations for restaurants and travel, as well as associated services in the US, the Netherlands, and other countries. While we acknowledge the potential of BKNG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
